Acromegaly in a patient with a pulmonary neuroendocrine tumor: case report and review of current literature

Krug, Sebastian; Boch, Michael; Rexin, Peter; Pfestroff, Andreas; Gress, Thomas M.; Michl, Patrick; Rinke, Anja

doi:10.1186/s13104-016-2132-1

Cited by 14 publications

(11 citation statements)

References 38 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ectopic secretion of GH from extra-pituitary tumors, causing less than 1% of acromegaly cases, was documented in case reports describing patients with bronchial or pancreatic neuroendocrine tumors and lymphomas [70,71,72,73]. There are also reports of ectopic acromegaly due to a GH-secreting pituitary tumor in the sphenoid sinus [74,75].…”

Section: Extra-pituitary Tumorsmentioning

confidence: 99%

The Clinicopathological Spectrum of Acromegaly

Akirov

Sylvia

Amer

et al. 2019

JCM

View full text Add to dashboard Cite

Background: Acromegaly results from a persistent excess in growth hormone with clinical features that may be subtle or severe. The most common cause of acromegaly is a pituitary tumor that causes excessive production of growth hormone (GH), and rare cases are due to an excess of the GH-releasing hormone (GHRH) or the ectopic production of GH. Objective: Discuss the different diseases that present with manifestations of GH excess and clinical acromegaly, emphasizing the distinct clinical and radiological characteristics of the different pathological entities. Methods: We performed a narrative review of the published clinicopathological information about acromegaly. An English-language search for relevant studies was conducted on PubMed from inception to 1 August 2019. The reference lists of relevant studies were also reviewed. Results: Pituitary tumors that cause GH excess have several variants, including pure somatotroph tumors that can be densely or sparsely granulated, or plurihormonal tumors that include mammosomatotroph, mixed somatotroph-lactotroph tumors and mature plurihomonal Pit1-lineage tumors, acidophil stem cell tumors and poorly-differentiated Pit1-lineage tumors. Each tumor type has a distinct pathophysiology, resulting in variations in clinical manifestations, imaging and responses to therapies. Conclusion: Detailed clinicopathological information will be useful in the era of precision medicine, in which physicians tailor the correct treatment modality to each patient.

show abstract

Section: Extra-pituitary Tumorsmentioning

confidence: 99%

The Clinicopathological Spectrum of Acromegaly

Akirov

Sylvia

Amer

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…On the other hand, paraneoplastic acromegaly was described in pulmonary neuroendocrine tumors [ 15 ]. Laboratory tests revealed markedly increased growth hormone (GH) and insulin-like growth factor 1 (IGF-1) without GHRH elevation.…”

Section: Discussionmentioning

confidence: 99%

An unusual clinical manifestation of a relapsed typical pulmonary carcinoϊd tumor

Belloumi

Hamdi

Braham

et al. 2021

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

Typical carcinoid tumors of the lungs carry an excellent prognosis after complete surgical excision. However, recurrence of these cancers remains poorly described in the literature and may occur many years after surgery. We report a case of carcinoid tumor of the lung. Clinical presentation and follow-up were uneventful. The 55 years old patient had got a surgical removal of a huge typical carcinoid tumor of the left lung. A left pneumonectomy with a mediastinal lymph node resection were performed. Thirteen years later, paraneoplastic acromegaly revealed a pulmonary and extrapulmonary recurrence of the tumor. We prescribed a chemotherapy regimen including Cisplatin and Etoposide. Endocrine paraneoplastic syndromes are related to mutations in specifically known genes. Several mutations may become a promising therapeutic target in the future. In the case of neuro-endocrine pulmonary tumors, authors described BCOR gene mutation as an oncogenic development inducer and an eventual generator of ectopic tumoral secretions. The more we get familiar with carcinoid tumor mutations, the closer we get to targeted therapy for non-resectable tumors.

show abstract

“…The 5-year survival rate was 53% and the median PFS was 11.1 months. 50 Another recent study published in 2021 included 31 patients with a fairly equal number of AC (17) and TC ( 14) tumors. This study demonstrated SD in 77.4% of patients with a median PFS of 28.6 months.…”

Section: A) Somatostatin Analog Therapymentioning

confidence: 99%

“…Abbreviations: BPNET, Bronchopulmonary Neuroendocrine Tumor and insulin-growth factor 2. 17,18 There is limited utility of routine baseline plasma chromogranin A (CgA) testing in patients with BPNETs and poor correlation with disease status. 19 CgA can also be falsely elevated with renal impairment, atrophic gastritis, and the use of proton pump inhibitors.…”

Section: Introductionmentioning

confidence: 99%